XBiotech Inc
XBITBuild a strategy around XBIT
XBiotech Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue pre-clinical biotech with 147.4M cash, burning 23.5M/year TTM - ~6.3 years runway at current rate[Cash and Equivalents]
- Trading at 0.44x book value (73.2M market cap vs 167.1M equity) - market pricing in significant failure risk[P/B Ratio]
- Negative EV (-74.2M) means cash exceeds market cap by 2x - pure optionality play on pipeline[Enterprise Value]
Watch Triggers
- Cash and Equivalents: Falls below 100M or burn rate exceeds 30M/year — Runway compression below 3 years would force dilutive financing
- R&D TTM: Significant increase or decrease from 29.9M baseline — Signals pipeline advancement (bullish) or program termination (bearish)
- Total Revenue TTM: Any revenue recognition above zero — Would indicate licensing deal, partnership, or product approval
Bull Case
Negative EV (-74.2M) means you're paid to own the pipeline - any clinical success creates massive upside from deeply discounted base
Clean balance sheet (zero debt, 167M equity) with 6+ years runway eliminates near-term dilution/bankruptcy risk
Bear Case
Zero revenue with -29.2M net loss TTM - entirely dependent on clinical trial success with binary outcomes
ROE of -16.2% and ROA of -15.3% TTM destroying shareholder value; market cap below cash suggests low confidence in pipeline
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage XBIT's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Cash runway provides 6+ years to achieve clinical milestones without dilution
- 147.4M cash vs 23.5M annual burn TTM
- Zero debt, minimal capex (339K TTM)
- R&D spend of 29.9M focused on pipeline
Valuation Context
Caveats
Public Strategies Rankings
See how XBiotech Inc ranks across different investment strategies.
Leverage XBIT's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
XBIT Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$68.6M | — | ||
$-78.77M | — | ||
0.00 | — | ||
$0 | — | ||
$-0.95 | — | ||
0% | 0.0% | — | |
0% | 0.0% | — | |
$-23.85M | — | ||
-16.2% | -0.5% | — | |
Beta 5Y (Monthly) | unknown | — |
XBIT Dividend History
2021
$2.4700XBIT Stock Splits
XBIT SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/12/25 | 09/30/25 | 10-Q | |
08/13/25 | 06/30/25 | 10-Q | |
05/14/25 | 03/31/25 | 10-Q | |
03/18/25 | 12/31/24 | Unknown | |
11/13/24 | 09/30/24 | 10-Q | |
08/12/24 | 06/30/24 | 10-Q | |
05/10/24 | 03/31/24 | 10-Q | |
03/15/24 | 12/31/23 | 10-K | |
11/09/23 | 09/30/23 | 10-Q | |
08/11/23 | 06/30/23 | 10-Q | |
05/10/23 | 03/31/23 | 10-Q | |
03/15/23 | 12/31/22 | 10-K | |
11/09/22 | 09/30/22 | 10-Q | |
08/10/22 | 06/30/22 | 10-Q | |
05/10/22 | 03/31/22 | 10-Q | |
03/15/22 | 12/31/21 | 10-K | |
11/09/21 | 09/30/21 | 10-Q | |
08/09/21 | 06/30/21 | 10-Q | |
05/10/21 | 03/31/21 | 10-Q | |
03/16/21 | 12/31/20 | 10-K | |
11/09/20 | 09/30/20 | 10-Q | |
08/10/20 | 06/30/20 | 10-Q | |
05/11/20 | 03/31/20 | 10-Q | |
03/16/20 | 12/31/19 | 10-K | |
11/12/19 | 09/30/19 | 10-Q | |
08/09/19 | 06/30/19 | 10-Q | |
05/09/19 | 03/31/19 | 10-Q | |
03/14/19 | 12/31/18 | 10-K | |
10/31/18 | 09/30/18 | 10-Q | |
08/09/18 | 06/30/18 | 10-Q | |
05/08/18 | 03/31/18 | 10-Q | |
03/16/18 | 12/31/17 | 10-K | |
11/09/17 | 09/30/17 | 10-Q | |
08/08/17 | 06/30/17 | 10-Q | |
05/10/17 | 03/31/17 | 10-Q | |
03/16/17 | 12/31/16 | 10-K | |
11/14/16 | 09/30/16 | 10-Q | |
08/12/16 | 06/30/16 | 10-Q | |
05/13/16 | 03/31/16 | 10-Q | |
03/30/16 | 12/31/15 | 10-K | |
11/13/15 | 09/30/15 | 10-Q | |
08/14/15 | 06/30/15 | 10-Q | |
05/27/15 | 03/31/15 | 10-Q | |
04/16/15 | 12/31/14 | 424B4 | |
02/02/15 | 09/30/14 | S-1 | |
08/14/15 | 06/30/14 | 10-Q | |
05/27/15 | 03/31/14 | 10-Q | |
04/15/16 | 12/31/13 | 10-K/A |